Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242727 | 0.89 | BACE1 (0.37) | BACE1 | |
| SCHEMBL3245524 | 0.89 | HCAR2 (0.31) | BACE1HCAR2 | |
| SCHEMBL3240569 | 0.88 | BACE1 (0.32) | BACE1HCAR2 | |
| SCHEMBL3245129 | 0.86 | KDM1A (0.31) | KDM1AALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL3239146 | 0.85 | P2RX7 (0.34) | BACE1KCNH2LOXLOXL2 | |
| SCHEMBL3243721 | 0.85 | GCK (0.33) | BACE1ALOX15TSHRMAPK1HSD17B10 | |
| SCHEMBL3239193 | 0.84 | BACE1 (0.35) | BACE1 | |
| SCHEMBL3357425 | 0.83 | — | — | |
| SCHEMBL3244330 | 0.82 | BACE1 (0.35) | BACE1 | |
| SCHEMBL3357409 | 0.80 | BACE1 (0.42) | BACE1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | claimed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | claimed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | PSEN1, PSEN2, BACE1 | BACE1 3/4885KCNH2 4652/4885KDM1A 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.